CVRx Q4 revenue $11.3M (+58% YoY); CEO Nadim Yared to retire; FY23 rev $39.3M (+75%)

CVRx, Inc.

2023-FY EPS reported -$1.99 revenue$39,295,000

Q4 revenue $11.3M (+58% YoY); US HF revenue $10.2M (+70% YoY).
FY23 revenue $39.3M (+75% YoY); net loss $41.2M ($1.99/share); cash $90.6M.
Active implanting centers 178 at year-end, up from 106 in prior year.
CEO Nadim Yared announces retirement; board to conduct succession search; Yared stays until successor appointed.
FDA approved expanded Barostim labeling; CMS increased outpatient payment to ~$45,000; market opportunity updated to $2.2B annually.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CVRx, Inc. updated its the quarter and year ended December 31, 2023 guidance (reaffirmed).

Period: the quarter and year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On January 25, 2024, CVRx, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

53 earnings releases filed in the last 30 days. Browse all earnings releases →

CVRx, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-006675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.